Trital SR

Name: Trital SR

Trital SR Description

Each extended release tablet for oral administration contains:

Acetaminophen 325 mg
Chlorpheniramine Maleate 8 mg
Phenylephrine HCl 40 mg
Phenyltoloxamine Citrate 50 mg

in a specially prepared base, to provide a prolonged therapeutic effect.

Acetaminophen, 4'-Hydroxyacetanilide, is a non-opiate, non-salicylate. It has the following structural formula:

C8H9NO2    M.W. 151.16

Chlorpheniramine maleate, 2-Pyridinepropanamine, γ-(4-chlorphenyl)-N,N-dimethyl-, (Z)-2-butenedioate (1:1), is an antihistamine. It has the following structural formula:

C16H19CIN2 • C4H4O4    M.W. 390.86

Phenylephrine hydrochloride, Benzenemethanol, 3-hydroxy- α-[(methylamino) methyl]-, hydrochloride (R)-, is a sympathomimetic amine. It has the following structural formula:

C9H13NO2 • HCL    M.W.=203.67

Phenyltoloxamine citrate, N, N-dimethyl-2- (α-phenyl-o-tolyloxy) ethylamine dihydrogen citrate, is an adjuvant to acetaminophen. it has the following structural formula:

C17H21NO • C6H8O7    M.W. 447.47

Also includes the following as inactive ingredients: croscarmellose sodium, dicalcium phosphate, 1FD&C yellow No. 5, hypromellose, microcrystalline cellulose, silicon dioxide, stearic acid and talc.

1 This product contains FD&C yellow No. 5 (Tartrazine) as a color additive.
(See PRECAUTIONS, Information for Patients).

Trital SR - Clinical Pharmacology

The mechanism of analgesic action of acetaminophen has not been fully determined. Acetaminophen may act by inhibiting prostaglandin synthesis in the central nervous system (CNS) and, through peripheral action, by blocking pain-impulse generation. The peripheral action may be due to inhibition of the syntheses of prostaglandins or to inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation.

Chlorpheniramine maleate is an alkylamine-type antihistamine. This group of antihistamines is among the most active histamine antagonists and are generally effective in relatively low doses.

Phenylephrine hydrochloride is primarily a direct acting sympathomimetic amine.

Sympathomimetic amines act on alpha adrenergic receptors in the mucosa of the respiratory tract to produce vasoconstriction, which temporarily reduces the swelling associated with inflammation of the mucous membranes lining the nasal passages. Phenyltoloxamine citrate is an ethanol amine-type compound used as an adjuvant with acetaminophen to mediate the release of bradykinin and prostaglandin, two agents involved in the cause of inflammatory pain.

Contraindications

Trital™ SR should not be administered to patients who have previously exhibited hypersensitivity to any of the ingredients Risk-benefit should be considered when any of the following medical problems exist: alcoholism, asthma, bladder-neck obstruction, urinary retention, cardiovascular disease, diabetes mellitus, glaucoma, hepatic function impairment, hypertension, hyperthyroidism, prostatic hypertrophy, psychosis or other psychiatric disorders, renal function impairment, viral hepatitis.

Warnings

Do not exceed recommended dosage. If nervousness, dizziness or sleeplessness occurs, discontinue use and consult a doctor. If symptoms do not improve within 7 days or are accompanied by a fever, consult a doctor. If pain or fever persist, if new symptoms occur, or if redness or swelling is present, consult your physician immediately because these could be signs of a serious condition. Do not give this product to children under 12 years of age. Caution should be exercised when used in patients with prostatic hypertrophy, urinary retention, bladder neck obstruction, increased ocular pressure and asthma.

Alcohol Warning

If you consume 3 or more alcoholic drinks every day, ask you doctor whether you should take acetaminophen or other pain relievers/ fever reducers. Acetaminophen may cause liver damage.

How is Trital SR Supplied

Trital™ SR is a yellow, triangle-shaped tablet debossed B529 on one side and scored on the opposite. Available in bottles of 100, NDC 51991-529-01.

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). See USP Controlled Room Temperature.

Dispense in tight, light-resistant containers as defined in the USP/NF with a child-resistant closure.

KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.

All prescription substitutions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

Distributed by:
Breckenridge Pharmaceutical, Inc.
Boca Raton, FL 33487

Manufactured by:
Provident Pharmaceuticals, LLC
Colorado Springs, CO 80919

PI235

Iss: 02/08

PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label

Breckenridge
Pharmaceutical, Inc.

NDC 51991-529-01

Trital™ SR

Antihistamine/Analgesic
Decongestant

Each extended release tablet for oral
administration contains:

Acetaminophen 325 mg
Chlorpheniramine Maleate 8 mg
Phenylephrine HCl 40 mg
Phenyltoloxamine Citrate 50 mg

100 TABLETS
Rx Only

Trital SR 
acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride, and phenyltoloxamine citrate tablet, extended release
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:51991-529
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Acetaminophen (Acetaminophen) Acetaminophen 325 mg
Chlorpheniramine Maleate (Chlorpheniramine) Chlorpheniramine Maleate 8 mg
Phenylephrine Hydrochloride (Phenylephrine) Phenylephrine Hydrochloride 40 mg
Phenyltoloxamine Citrate (Phenyltoloxamine) Phenyltoloxamine Citrate 50 mg
Inactive Ingredients
Ingredient Name Strength
Croscarmellose Sodium  
Anhydrous Dibasic Calcium Phosphate  
FD&C Yellow No. 5  
Hypromelloses  
Cellulose, Microcrystalline  
Silicon Dioxide  
Stearic Acid  
Talc  
Product Characteristics
Color YELLOW Score 2 pieces
Shape TRIANGLE Size 12mm
Flavor Imprint Code B;529
Contains     
Packaging
# Item Code Package Description
1 NDC:51991-529-01 100 TABLET, EXTENDED RELEASE (TABLET) in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 03/01/2008 05/31/2011
Labeler - Breckenridge Pharmaceutical, Inc. (150554335)
Establishment
Name Address ID/FEI Operations
Provident Pharms Inc 171901445 MANUFACTURE
Revised: 01/2011   Breckenridge Pharmaceutical, Inc.
(web3)